Pharmacokinetics of β‑Lactam Antibiotics: Clues from the Past To Help Discover Long-Acting Oral Drugs in the Future

β-Lactams represent perhaps the most important class of antibiotics yet discovered. However, despite many years of active research, none of the currently approved drugs in this class combine oral activity with long duration of action. Recent developments suggest that new β-lactam antibiotics with su...

Full description

Saved in:
Bibliographic Details
Published in:ACS infectious diseases 2018-10, Vol.4 (10), p.1439-1447
Main Authors: Smith, Paul W., Zuccotto, Fabio, Bates, Robert H., Martinez-Martinez, Maria Santos, Read, Kevin D., Peet, Caroline, Epemolu, Ola
Format: Article
Language:English
Subjects:
Administration, Oral
Animals
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - classification
Anti-Bacterial Agents - pharmacokinetics
Anti-Bacterial Agents - therapeutic use
beta-Lactams - administration & dosage
beta-Lactams - classification
beta-Lactams - pharmacokinetics
beta-Lactams - therapeutic use
Biological Availability
Cell Membrane Permeability - drug effects
Drug Discovery - methods
Half-Life
Haplorhini
Humans
Mycobacterium tuberculosis - drug effects
Protein Binding
Retrospective Studies
Solubility
Treatment Outcome
Tuberculosis - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a445t-3fec0d707db4946c73fa70b0957ddf8633cf260d9bc0a7e391e644eb87e64df83
cites cdi_FETCH-LOGICAL-a445t-3fec0d707db4946c73fa70b0957ddf8633cf260d9bc0a7e391e644eb87e64df83
container_end_page 1447
container_issue 10
container_start_page 1439
container_title ACS infectious diseases
container_volume 4
creator Smith, Paul W.
Zuccotto, Fabio
Bates, Robert H.
Martinez-Martinez, Maria Santos
Read, Kevin D.
Peet, Caroline
Epemolu, Ola
description β-Lactams represent perhaps the most important class of antibiotics yet discovered. However, despite many years of active research, none of the currently approved drugs in this class combine oral activity with long duration of action. Recent developments suggest that new β-lactam antibiotics with such a profile would have utility in the treatment of tuberculosis. Consequently, the historical β-lactam pharmacokinetic data have been compiled and analyzed to identify possible directions and drug discovery strategies aimed toward new β-lactam antibiotics with this profile.
doi_str_mv 10.1021/acsinfecdis.8b00160
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6189874</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2093401433</sourcerecordid><originalsourceid>FETCH-LOGICAL-a445t-3fec0d707db4946c73fa70b0957ddf8633cf260d9bc0a7e391e644eb87e64df83</originalsourceid><addsrcrecordid>eNp9UUtOwzAUtBCIVtATICEv2QTs2I0TFkhV-UqVYAFry3Gc1iWxi-1UYscVuAoH4RCcBEMLKhtWz9KbGc-8AeAAo2OMUnwipNemVrLS_jgvEcIZ2gL9lDCS5GnKtjfePTDwfo4ihuRDSoe7oEcQprhAaR8s72bCtULaR21U0NJDW8P3t4-X14mQQbRwZIIutf1ancJx0ykPa2dbGGYK3gkf4L2F16pZwHPtpV0qByfWTJORDNpM4a0TDTx33dRDbb45l13onNoHO7VovBqs5x54uLy4H18nk9urm_FokohoNCQkJkQVQ6wqaUEzyUgtGCpRMWRVVecZIbJOM1QVpUSCKVJglVGqypzFGQFkD5ytdBdd2apKKhOiI75wuhXumVuh-d-N0TM-tUue4bzIGY0CR2sBZ59i-MDbmFM1jTDKdp6nqCA0XpOQCCUrqHTWe6fq328w4l-l8Y3S-Lq0yDrcdPjL-akoAk5WgMjmc9s5Ew_2r-QnH36pXw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2093401433</pqid></control><display><type>article</type><title>Pharmacokinetics of β‑Lactam Antibiotics: Clues from the Past To Help Discover Long-Acting Oral Drugs in the Future</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read &amp; Publish Agreement 2022-2024 (Reading list)</source><creator>Smith, Paul W. ; Zuccotto, Fabio ; Bates, Robert H. ; Martinez-Martinez, Maria Santos ; Read, Kevin D. ; Peet, Caroline ; Epemolu, Ola</creator><creatorcontrib>Smith, Paul W. ; Zuccotto, Fabio ; Bates, Robert H. ; Martinez-Martinez, Maria Santos ; Read, Kevin D. ; Peet, Caroline ; Epemolu, Ola</creatorcontrib><description>β-Lactams represent perhaps the most important class of antibiotics yet discovered. However, despite many years of active research, none of the currently approved drugs in this class combine oral activity with long duration of action. Recent developments suggest that new β-lactam antibiotics with such a profile would have utility in the treatment of tuberculosis. Consequently, the historical β-lactam pharmacokinetic data have been compiled and analyzed to identify possible directions and drug discovery strategies aimed toward new β-lactam antibiotics with this profile.</description><identifier>ISSN: 2373-8227</identifier><identifier>EISSN: 2373-8227</identifier><identifier>DOI: 10.1021/acsinfecdis.8b00160</identifier><identifier>PMID: 30141902</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Administration, Oral ; Animals ; Anti-Bacterial Agents - administration &amp; dosage ; Anti-Bacterial Agents - classification ; Anti-Bacterial Agents - pharmacokinetics ; Anti-Bacterial Agents - therapeutic use ; beta-Lactams - administration &amp; dosage ; beta-Lactams - classification ; beta-Lactams - pharmacokinetics ; beta-Lactams - therapeutic use ; Biological Availability ; Cell Membrane Permeability - drug effects ; Drug Discovery - methods ; Half-Life ; Haplorhini ; Humans ; Mycobacterium tuberculosis - drug effects ; Protein Binding ; Retrospective Studies ; Solubility ; Treatment Outcome ; Tuberculosis - drug therapy</subject><ispartof>ACS infectious diseases, 2018-10, Vol.4 (10), p.1439-1447</ispartof><rights>Copyright © 2018 American Chemical Society 2018 American Chemical Society</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a445t-3fec0d707db4946c73fa70b0957ddf8633cf260d9bc0a7e391e644eb87e64df83</citedby><cites>FETCH-LOGICAL-a445t-3fec0d707db4946c73fa70b0957ddf8633cf260d9bc0a7e391e644eb87e64df83</cites><orcidid>0000-0002-8536-0130 ; 0000-0002-0146-1410</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30141902$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Smith, Paul W.</creatorcontrib><creatorcontrib>Zuccotto, Fabio</creatorcontrib><creatorcontrib>Bates, Robert H.</creatorcontrib><creatorcontrib>Martinez-Martinez, Maria Santos</creatorcontrib><creatorcontrib>Read, Kevin D.</creatorcontrib><creatorcontrib>Peet, Caroline</creatorcontrib><creatorcontrib>Epemolu, Ola</creatorcontrib><title>Pharmacokinetics of β‑Lactam Antibiotics: Clues from the Past To Help Discover Long-Acting Oral Drugs in the Future</title><title>ACS infectious diseases</title><addtitle>ACS Infect. Dis</addtitle><description>β-Lactams represent perhaps the most important class of antibiotics yet discovered. However, despite many years of active research, none of the currently approved drugs in this class combine oral activity with long duration of action. Recent developments suggest that new β-lactam antibiotics with such a profile would have utility in the treatment of tuberculosis. Consequently, the historical β-lactam pharmacokinetic data have been compiled and analyzed to identify possible directions and drug discovery strategies aimed toward new β-lactam antibiotics with this profile.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Anti-Bacterial Agents - administration &amp; dosage</subject><subject>Anti-Bacterial Agents - classification</subject><subject>Anti-Bacterial Agents - pharmacokinetics</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>beta-Lactams - administration &amp; dosage</subject><subject>beta-Lactams - classification</subject><subject>beta-Lactams - pharmacokinetics</subject><subject>beta-Lactams - therapeutic use</subject><subject>Biological Availability</subject><subject>Cell Membrane Permeability - drug effects</subject><subject>Drug Discovery - methods</subject><subject>Half-Life</subject><subject>Haplorhini</subject><subject>Humans</subject><subject>Mycobacterium tuberculosis - drug effects</subject><subject>Protein Binding</subject><subject>Retrospective Studies</subject><subject>Solubility</subject><subject>Treatment Outcome</subject><subject>Tuberculosis - drug therapy</subject><issn>2373-8227</issn><issn>2373-8227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9UUtOwzAUtBCIVtATICEv2QTs2I0TFkhV-UqVYAFry3Gc1iWxi-1UYscVuAoH4RCcBEMLKhtWz9KbGc-8AeAAo2OMUnwipNemVrLS_jgvEcIZ2gL9lDCS5GnKtjfePTDwfo4ihuRDSoe7oEcQprhAaR8s72bCtULaR21U0NJDW8P3t4-X14mQQbRwZIIutf1ancJx0ykPa2dbGGYK3gkf4L2F16pZwHPtpV0qByfWTJORDNpM4a0TDTx33dRDbb45l13onNoHO7VovBqs5x54uLy4H18nk9urm_FokohoNCQkJkQVQ6wqaUEzyUgtGCpRMWRVVecZIbJOM1QVpUSCKVJglVGqypzFGQFkD5ytdBdd2apKKhOiI75wuhXumVuh-d-N0TM-tUue4bzIGY0CR2sBZ59i-MDbmFM1jTDKdp6nqCA0XpOQCCUrqHTWe6fq328w4l-l8Y3S-Lq0yDrcdPjL-akoAk5WgMjmc9s5Ew_2r-QnH36pXw</recordid><startdate>20181012</startdate><enddate>20181012</enddate><creator>Smith, Paul W.</creator><creator>Zuccotto, Fabio</creator><creator>Bates, Robert H.</creator><creator>Martinez-Martinez, Maria Santos</creator><creator>Read, Kevin D.</creator><creator>Peet, Caroline</creator><creator>Epemolu, Ola</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8536-0130</orcidid><orcidid>https://orcid.org/0000-0002-0146-1410</orcidid></search><sort><creationdate>20181012</creationdate><title>Pharmacokinetics of β‑Lactam Antibiotics: Clues from the Past To Help Discover Long-Acting Oral Drugs in the Future</title><author>Smith, Paul W. ; Zuccotto, Fabio ; Bates, Robert H. ; Martinez-Martinez, Maria Santos ; Read, Kevin D. ; Peet, Caroline ; Epemolu, Ola</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a445t-3fec0d707db4946c73fa70b0957ddf8633cf260d9bc0a7e391e644eb87e64df83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Anti-Bacterial Agents - administration &amp; dosage</topic><topic>Anti-Bacterial Agents - classification</topic><topic>Anti-Bacterial Agents - pharmacokinetics</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>beta-Lactams - administration &amp; dosage</topic><topic>beta-Lactams - classification</topic><topic>beta-Lactams - pharmacokinetics</topic><topic>beta-Lactams - therapeutic use</topic><topic>Biological Availability</topic><topic>Cell Membrane Permeability - drug effects</topic><topic>Drug Discovery - methods</topic><topic>Half-Life</topic><topic>Haplorhini</topic><topic>Humans</topic><topic>Mycobacterium tuberculosis - drug effects</topic><topic>Protein Binding</topic><topic>Retrospective Studies</topic><topic>Solubility</topic><topic>Treatment Outcome</topic><topic>Tuberculosis - drug therapy</topic><toplevel>online_resources</toplevel><creatorcontrib>Smith, Paul W.</creatorcontrib><creatorcontrib>Zuccotto, Fabio</creatorcontrib><creatorcontrib>Bates, Robert H.</creatorcontrib><creatorcontrib>Martinez-Martinez, Maria Santos</creatorcontrib><creatorcontrib>Read, Kevin D.</creatorcontrib><creatorcontrib>Peet, Caroline</creatorcontrib><creatorcontrib>Epemolu, Ola</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>ACS infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Smith, Paul W.</au><au>Zuccotto, Fabio</au><au>Bates, Robert H.</au><au>Martinez-Martinez, Maria Santos</au><au>Read, Kevin D.</au><au>Peet, Caroline</au><au>Epemolu, Ola</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacokinetics of β‑Lactam Antibiotics: Clues from the Past To Help Discover Long-Acting Oral Drugs in the Future</atitle><jtitle>ACS infectious diseases</jtitle><addtitle>ACS Infect. Dis</addtitle><date>2018-10-12</date><risdate>2018</risdate><volume>4</volume><issue>10</issue><spage>1439</spage><epage>1447</epage><pages>1439-1447</pages><issn>2373-8227</issn><eissn>2373-8227</eissn><abstract>β-Lactams represent perhaps the most important class of antibiotics yet discovered. However, despite many years of active research, none of the currently approved drugs in this class combine oral activity with long duration of action. Recent developments suggest that new β-lactam antibiotics with such a profile would have utility in the treatment of tuberculosis. Consequently, the historical β-lactam pharmacokinetic data have been compiled and analyzed to identify possible directions and drug discovery strategies aimed toward new β-lactam antibiotics with this profile.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>30141902</pmid><doi>10.1021/acsinfecdis.8b00160</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-8536-0130</orcidid><orcidid>https://orcid.org/0000-0002-0146-1410</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2373-8227
ispartof ACS infectious diseases, 2018-10, Vol.4 (10), p.1439-1447
issn 2373-8227
2373-8227
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6189874
source American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)
subjects Administration, Oral
Animals
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - classification
Anti-Bacterial Agents - pharmacokinetics
Anti-Bacterial Agents - therapeutic use
beta-Lactams - administration & dosage
beta-Lactams - classification
beta-Lactams - pharmacokinetics
beta-Lactams - therapeutic use
Biological Availability
Cell Membrane Permeability - drug effects
Drug Discovery - methods
Half-Life
Haplorhini
Humans
Mycobacterium tuberculosis - drug effects
Protein Binding
Retrospective Studies
Solubility
Treatment Outcome
Tuberculosis - drug therapy
title Pharmacokinetics of β‑Lactam Antibiotics: Clues from the Past To Help Discover Long-Acting Oral Drugs in the Future
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T04%3A07%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacokinetics%20of%20%CE%B2%E2%80%91Lactam%20Antibiotics:%20Clues%20from%20the%20Past%20To%20Help%20Discover%20Long-Acting%20Oral%20Drugs%20in%20the%20Future&rft.jtitle=ACS%20infectious%20diseases&rft.au=Smith,%20Paul%20W.&rft.date=2018-10-12&rft.volume=4&rft.issue=10&rft.spage=1439&rft.epage=1447&rft.pages=1439-1447&rft.issn=2373-8227&rft.eissn=2373-8227&rft_id=info:doi/10.1021/acsinfecdis.8b00160&rft_dat=%3Cproquest_pubme%3E2093401433%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a445t-3fec0d707db4946c73fa70b0957ddf8633cf260d9bc0a7e391e644eb87e64df83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2093401433&rft_id=info:pmid/30141902&rfr_iscdi=true